Healthcare Asia on MSN29m
Cell and Gene therapy market to grow by $6.56b through 2028High cost is a major challenge. The global cell and gene therapy market is projected to expand by $6.56b, reflecting an ...
PTC Therapeutics’ gene therapy, Kebilidi to treat AADC deficiency receives US FDA approval: Warren, New Jersey Friday, November 15, 2024, 10:00 Hrs [IST] PTC Therapeutics, Inc., ...
A Summerville man became the first person in South Carolina to undergo potentially life-changing gene therapy.
Gene therapy can effectively treat various diseases, but for some debilitating conditions like muscular dystrophies there is a big problem: size.
Kebilidi is the first approved gene therapy that can be directly administered to the brain. Its OK secures a priority review ...
Tel Aviv University researchers have made a discovery that could enhance our understanding of genetic mutations and their ...
The Food and Drug Administration (FDA) has granted accelerated approval to Kebilidi™ (eladocagene exuparvovec-tneq) for the treatment of adult and pediatric patients with aromatic L-amino acid ...
Gene therapy can effectively treat various diseases, but for some debilitating conditions like muscular dystrophies there is ...
PTC Therapeutics' Kebilidi gains FDA accelerated approval as the first brain-administered gene therapy in the U.S. for AADC ...
This is the first gene therapy for AADC deficiency to receive US regulatory approval and the first that can be administered directly to the brain.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback